Cargando…
Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
OBJECTIVE: To evaluate the safety and efficacy of a humanized anti–interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO). METHODS: Seven patients with anti–aquaporin-4 antibody (AQP4-Ab)-positive NMO or NMO spectrum disorders were recruited on the basis of t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001188/ https://www.ncbi.nlm.nih.gov/pubmed/24634453 http://dx.doi.org/10.1212/WNL.0000000000000317 |
_version_ | 1782313709442433024 |
---|---|
author | Araki, Manabu Matsuoka, Takako Miyamoto, Katsuichi Kusunoki, Susumu Okamoto, Tomoko Murata, Miho Miyake, Sachiko Aranami, Toshimasa Yamamura, Takashi |
author_facet | Araki, Manabu Matsuoka, Takako Miyamoto, Katsuichi Kusunoki, Susumu Okamoto, Tomoko Murata, Miho Miyake, Sachiko Aranami, Toshimasa Yamamura, Takashi |
author_sort | Araki, Manabu |
collection | PubMed |
description | OBJECTIVE: To evaluate the safety and efficacy of a humanized anti–interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO). METHODS: Seven patients with anti–aquaporin-4 antibody (AQP4-Ab)-positive NMO or NMO spectrum disorders were recruited on the basis of their limited responsiveness to their current treatment. They were given a monthly injection of TCZ (8 mg/kg) with their current therapy for a year. We evaluated the annualized relapse rate, the Expanded Disability Status Scale score, and numerical rating scales for neurogenic pain and fatigue. Serum levels of anti-AQP4-Ab were measured with AQP4-transfected cells. RESULTS: Six females and one male with NMO were enrolled. After a year of TCZ treatment, the annualized relapse rate decreased from 2.9 ± 1.1 to 0.4 ± 0.8 (p < 0.005). The Expanded Disability Status Scale score, neuropathic pain, and general fatigue also declined significantly. The ameliorating effects on intractable pain exceeded expectations. CONCLUSION: Interleukin-6 receptor blockade is a promising therapeutic option for NMO. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with NMO, TCZ reduces relapse rate, neuropathic pain, and fatigue. |
format | Online Article Text |
id | pubmed-4001188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-40011882014-05-09 Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study Araki, Manabu Matsuoka, Takako Miyamoto, Katsuichi Kusunoki, Susumu Okamoto, Tomoko Murata, Miho Miyake, Sachiko Aranami, Toshimasa Yamamura, Takashi Neurology Article OBJECTIVE: To evaluate the safety and efficacy of a humanized anti–interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO). METHODS: Seven patients with anti–aquaporin-4 antibody (AQP4-Ab)-positive NMO or NMO spectrum disorders were recruited on the basis of their limited responsiveness to their current treatment. They were given a monthly injection of TCZ (8 mg/kg) with their current therapy for a year. We evaluated the annualized relapse rate, the Expanded Disability Status Scale score, and numerical rating scales for neurogenic pain and fatigue. Serum levels of anti-AQP4-Ab were measured with AQP4-transfected cells. RESULTS: Six females and one male with NMO were enrolled. After a year of TCZ treatment, the annualized relapse rate decreased from 2.9 ± 1.1 to 0.4 ± 0.8 (p < 0.005). The Expanded Disability Status Scale score, neuropathic pain, and general fatigue also declined significantly. The ameliorating effects on intractable pain exceeded expectations. CONCLUSION: Interleukin-6 receptor blockade is a promising therapeutic option for NMO. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with NMO, TCZ reduces relapse rate, neuropathic pain, and fatigue. Lippincott Williams & Wilkins 2014-04-15 /pmc/articles/PMC4001188/ /pubmed/24634453 http://dx.doi.org/10.1212/WNL.0000000000000317 Text en © 2014 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Article Araki, Manabu Matsuoka, Takako Miyamoto, Katsuichi Kusunoki, Susumu Okamoto, Tomoko Murata, Miho Miyake, Sachiko Aranami, Toshimasa Yamamura, Takashi Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study |
title | Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study |
title_full | Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study |
title_fullStr | Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study |
title_full_unstemmed | Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study |
title_short | Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study |
title_sort | efficacy of the anti–il-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001188/ https://www.ncbi.nlm.nih.gov/pubmed/24634453 http://dx.doi.org/10.1212/WNL.0000000000000317 |
work_keys_str_mv | AT arakimanabu efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT matsuokatakako efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT miyamotokatsuichi efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT kusunokisusumu efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT okamototomoko efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT muratamiho efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT miyakesachiko efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT aranamitoshimasa efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy AT yamamuratakashi efficacyoftheantiil6receptorantibodytocilizumabinneuromyelitisopticaapilotstudy |